Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study
Authors' conclusion
In this first observational study of ICI-IA patients rechallenged with ICI, about half of the patients experienced ICI-IA flare/recurrence with a similar phenotype but occurring earlier than the initial ICI-IA
Study context
- Population
- Cancer patients with immune-related inflammatory arthritis (ICI-IA) who started a second ICI course >3 months after ICI discontinuation, four French university hospitals
- Participants
- 23 patients
- Outcome
- Frequency of ICI-IA flare/recurrence after ICI rechallenge
Methodological detailsfour French university hospitals
- Four French university hospitals
Main finding
As reported in the abstract
ICI-IA flare/recurrence
| Group | Value | Median time to flare/recurrence after rechallenge |
|---|---|---|
| ICI rechallenge | 52% | 1 month |
ICI rechallenge
Value52%
Median time to flare/recurrence after rechallenge1 month
Observational data: associations, not effects.
Further findings
Features at rechallenge by flare/recurrence status
- ICI-IA phenotype, disease activity and ICI-IA treatment at rechallenge did not differ according to flare/recurrence status
Original publication
Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study. RMD Open. Published 29 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →